Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk issues FY 2014 guidance in line with analysts' estimates

Thursday, 30 Jan 2014 01:30am EST 

Novo Nordisk A/S:Expects FY 2014 sales growth measured in local currencies to be 8-11 percent, whereas operating profit growth measured in local currencies to be around 10 percent.Says FY 2013 sales result was 83,572 million Danish crowns and operating profit was 31,493 million Danish crowns.FY 2014 revenue 90,299 million Danish crowns, EBIT 34,530 million Danish crowns-Thomson reuters I/B/E/S Estimates.